The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of immune-checkpoint inhibitor (ICI) combination as a first-line (1L) therapy in metastatic renal cell carcinoma (mRCC) with sarcomatoid histology: A systematic review and meta-analysis.
 
Rabbia Siddiqi
No Relationships to Disclose
 
Gaurav Kumar
No Relationships to Disclose
 
Hafsah Ijaz
No Relationships to Disclose
 
Syed Arsalan Ahmed Naqvi
No Relationships to Disclose
 
Ahsan Ayaz
No Relationships to Disclose
 
Zaryab Bin Riaz
No Relationships to Disclose
 
Alan Haruo Bryce
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Castle Biosciences; Horizon CME; Myovant Sciences; Myovant Sciences; Pfizer; Research to Practice; Research to Practice; Verity Pharmaceuticals
Travel, Accommodations, Expenses - Clovis Oncology (Inst); Phosplatin Therapeutics (Inst)
 
Thai Huu Ho
Consulting or Advisory Role - Cardinal Health; Exelixis; Ipsen; Pfizer; Roche/Genentech; Surface Oncology
Research Funding - Novartis
 
Irbaz Bin Riaz
No Relationships to Disclose
 
Parminder Singh
Honoraria - Curio Science; Medpage/ASCO
Consulting or Advisory Role - AVEO; Bayer; EMD Serono; Janssen Oncology; Seattle Genetics/Astellas (Inst)
Research Funding - EMD Serono (Inst)
(OPTIONAL) Uncompensated Relationships - Seagen